Sinotau today announced that clinical data for XTR022 ([²²⁵Ac]Ac-XT381), its novel alpha-particle radioligand therapy, were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated the safety, tolerability and preliminary efficacy of XTR022 in patients with previously treated, PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Study Design […]
As the most important event in the global oncology field, the 2026 American Society of Clinical Oncology(ASCO) Anual Meeting will be held in Chicago from May 29 to June 2. Sinotau will present clinical research results of its independently developed novel alpha-particle radioligand therapy [225Ac]Ac-PSMA-XT for the treatment of metastatic castration-resistant prostate cancer (mCRPC) at […]
Sinotau is pleased to announce that the Investigational New Drug (IND) application for XTR021, a Class 1 innovative radiopharmaceutical developed in-house, has been accepted by the National Medical Products Administration (NMPA). XTR021 is a 177Lu-labeled, PSMA-targeted radioligand for the treatment of prostate cancer. Preclinical studies demonstrate that, owing to its novel molecular design, XTR021 exhibits […]
Sinotau is pleased to announce that the results of the Phase III clinical trial in China for our self-developed radionuclide therapeutic drug, ¹⁷⁷Lu-Dotatate(XTR008), have been officially published in the prestigious international oncology journal Annals of Oncology (Impact Factor: 65.4). Concurrently, the latest analysis results from this study were successfully selected as a Late-Breaking Abstract (LBA) for this […]
Recently, the Cardiovascular Imaging Professional Committee of the National Expert Committee on Cardiovascular Diseases was officially established. Initiated by experts including Academician Hu Shengshou and with Academician Wang Zhenchang serving as its first Chairman, the committee brings together hundreds of top experts in the field of cardiovascular imaging in China. Its establishment marks a new stage […]
The Annual Congress of the European Association of Nuclear Medicine (EANM), a top-tier academic conference in the global nuclear medicine field, will take place at the International Conference Centre in Barcelona, Spain on October 4-8, 2025. Focusing on cutting-edge topics in nuclear medicine, the EANM Congress is renowned for setting international clinical practice standards, and the guidelines it […]
Beijing, China —Beijing Sinotau International Pharmaceutical Technology Co. , Ltd. is pleased to announce that the innovative radiopharmaceutical XTR020 for prostate cancer diagnosis has recently completed the enrollment and dosing of all subjects in its Phase III clinical study in China, marking a significant milestone in the product’s research and development in China. Despite clear and […]
October 17-21, 2025– The European Society for Medical Oncology (ESMO) Congress, Europe’s most influential oncology conference, will be held in Berlin, Germany. The full results of the China Phase III registration clinical trial for Sinotau’s self-developed innovative radioconjugate (RDC) drug, XTR008, have been successfully selected as a Late-Breaking Abstract (LBA) and will be globally presented […]
BEIJING, China – September 8, 2025 – Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (“Sinotau”) is proud to announce that the Phase I, first-in-human study of self-developed innovative radiopharmaceutical XTR004, were awarded the Best Translational Paper Award – Molecular Imaging Category by the Journal of Nuclear Cardiology at the 30th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology (ASNC […]
Recently, Meilleur, a joint venture of Sinotau, that holds global rights to NAV-4694, an ß amyloid PET imaging agent for Alzheimer’s disease, was acquired by Lantheus. Recently published updated guidelines developed by a working group of the National Institute on Aging and the Alzheimer’s Association (NIA-AA) state that Alzheimer’s disease should be defined biologically, using protein-based biomarkers. These guidelines recommend that […]
First Amyloid PET Tracer Received Regulatory Approval in China
Beijing, China, October 17, 2023– the Press Conference on the Regulatory Approval of Florbetaben F 18 Injection, organized by Sinotau Pharmaceutical Group, the leading company of innovative radiopharmaceuticals in China, was successfully held in Beijing. Co-President Mrs. Yanmin Tang, Vice President and Secretary of the Board of Directors Mr. Wenbin Yu, Medical Marketing Director Mr.Xin Wang and other senior leaders of the company […]